NIH study finds two doses of HPV vaccine may be as protective as full course – 3
Narrator: This is NIH Health Matters. I’m Joe Balintfy. A clinical trial in Costa Rica has researchers suggesting that giving an HPV vaccine to more women, with fewer doses for each, could reduce cervical cancer incidence more than a standard three-dose program for fewer women. Dr. Aimée Kreimer at the NIH explains results after four years of follow-up.
Kreimer: What we observed was that the vaccine efficacy for women who received two doses or even a single dose was quite comparable to that of the standard regimen.
Narrator: She says further studies are needed to confirm the findings in other populations and to calculate how long protection lasts with fewer doses. For more information, visit www.cancer.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Audio
NIH Audio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Audio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Audio is a service of the Office of Communications & Public Liaison.